Literature DB >> 11733226

Pituitary tumors: pathophysiology, clinical manifestations and management.

B M Arafah1, M P Nasrallah.   

Abstract

Pituitary tumors are frequently encountered intracranial neoplasms. They present with a variety of clinical manifestations that include symptoms and signs of excessive hormone secretion by the tumor, signs of hormone deficits by the normal pituitary gland and others related to expansion of the tumor mass and the resulting compression of surrounding structures such as the optic chiasm and cranial nerves. Advances in molecular biology, immunocytochemical staining and imaging, and the introduction of new treatment options have improved our understanding of the natural history of these adenomas and their management. Available treatments include surgical, medical and radiation therapy. Although the primary treatment for each tumor type may vary, it is important to consider all available options and select the most applicable for that patient. The interaction of all members of management team, including the primary care provider, the endocrinologist and the neurosurgeon in selecting the treatment course can only improve therapeutic outcome. Regardless of the initial choice of treatment,follow-up of all patients should be maintained indefinitely. The managing physician should be familiar with the natural history and long-term complications of pituitary adenomas, and with the side effects of treatments given over the years.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11733226     DOI: 10.1677/erc.0.0080287

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  53 in total

Review 1.  The pituitary mass: diagnosis and management.

Authors:  Susan Sam; Mark E Molitch
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

2.  The epidemiology of prolactinomas.

Authors:  Antonio Ciccarelli; Adrian F Daly; Albert Beckers
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  GENE THERAPY FOR THE TREATMENT OF PITUITARY TUMORS.

Authors:  Silvia S Rodriguez; Maria G Castro; Oscar A Brown; Rodolfo G Goya; Gloria M Console
Journal:  Expert Rev Endocrinol Metab       Date:  2009-07-01

Review 4.  Prolactinoma through the female life cycle.

Authors:  Deirdre Cocks Eschler; Pedram Javanmard; Katherine Cox; Eliza B Geer
Journal:  Endocrine       Date:  2017-11-24       Impact factor: 3.633

Review 5.  Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas.

Authors:  Mansur E Shomali; Laurence Katznelson
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

6.  Suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in pituitary adenoma cells.

Authors:  S R Sangeetha; Nagendra Singh; John R Vender; Krishnan M Dhandapani
Journal:  Endocrine       Date:  2009-03-17       Impact factor: 3.633

Review 7.  Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors.

Authors:  Anelia Horvath; Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

8.  Mandibular prognathism caused by acromegaly - a surgical orthodontic case.

Authors:  Martin Gosau; Corinna Vogel; Antonios Moralis; Peter Proff; Johannes Kleinheinz; Oliver Driemel
Journal:  Head Face Med       Date:  2009-08-06       Impact factor: 2.151

9.  Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.

Authors:  Beverly Mk Biller; Annamaria Colao; Stephan Petersenn; Vivien S Bonert; Marco Boscaro
Journal:  BMC Endocr Disord       Date:  2010-05-17       Impact factor: 2.763

Review 10.  Familial isolated pituitary adenomas: an emerging clinical entity.

Authors:  F Martucci; G Trivellin; M Korbonits
Journal:  J Endocrinol Invest       Date:  2012-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.